BioInformant specializes in global strategic reports for the stem cell industry. As a specialty research company, we use technology to track and identify profitable opportunities within the stem cell sector and provide this data to clients pursuing aggressive growth.
Three Key Attributes that Set BioInformant Apart
1) We are the only market intelligence company that has served the stem cell sector since it emerged
Our singular focus on the stem cell industry allows us to produce data that enables you to better understand your markets, competitors, and customers.
While other publishers are often broad-scale publishers that cover a range of industry topics, we specialize exclusively in stem cell industry data. In contrast to other research firms, BioInformant has been collecting real-time data on the stem cell industry for nearly a decade. We have multiple 5-year periods for which we made stem cell industry projections and can compare our “projected” results to what “actually” occurred within the industry.
When choosing a provider of stem cell market intelligence, you should choose a research firm which has been tested and validated by both the market and the test of time.
2) BioInformant has been featured on prominent news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, CBS News, the California Institute for Regenerative Medicine (CIRM), and more
When choosing a provider of stem cell market intelligence, you should choose one that is trusted by industry experts.
It is a powerful way to screen for a high-quality source, because the publishing standards for prominent news outlets are stringent. This approach can provide an excellent way to have control over the quality of your data, especially in an industry that is highly-variable.
3) Our management team comes from a Bioinformatics background – the science of collecting and analyzing complex genetic codes
One thing that sets BioInformant apart is that our leadership team comes from a “Bioinformatics” background – the science of collecting and analyzing complex genetic codes. The field of Bioinformatics involves developing tools for managing and analyzing large quantities of biological data, such as the complete set of genes within a cell (Genomics), the complete set of proteins in a cell (Proteomics), and the complete set of compounds or substrates that are formed through enzymatic reactions within living systems (Metabolomics).
All of these areas involve huge, complex data-sets that must be examined in order to identity critical information. We are trained in applying these advanced research techniques to the field of market research.
It is this expertise in “Bioinformatics” from which we derived our company name, BioInformant.
Our skill set in Bioinformatics makes us uniquely positioned to:
- Define scope, definitions, and boundaries for the stem cell industry
- Collect relevant data from within this expansive system
- Extract relevant and critical information
- Identify key trends for purposes of predicting future activity
Additionally, we are uniquely suited to managing complex search queries within large global databases. Within the stem cell industry, this allows us to derive critical trend rate data from scientific publication databases, clinical trial databases, patent databases, grant funding databases, public blood/cell/tissue registries, transplant registries, and more.
In summary, Bioinformatics is an interdisciplinary field that develops methods and tools for processing complex biological data, while Market Research is an interdisciplinary field that develops methods and tools for analyzing complex industry data.
When performed effectively, these fields share many, if not all, of the same techniques.
BioInformant is the only research firm that has served the stem cell sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant has been featured on news outlets including the Wall Street Journal, Nature Biotechnology, Medical Ethics, CBS News, and the California Institute for Regenerative Medicine (CIRM). Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, Beckton Dickinson, and Thermo Fisher Scientific, BioInformant is your global leader in stem cell industry data.
To learn more about emerging trends and opportunities within the stem cell industry, view “Stem Cell Research Products – Opportunities, Tools, and Technologies” ” now.